- Home
- APWC vs NXTC Comparison
APWC vs NXTC Comparison
Compare APWC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APWC
- NXTC
- Stock Information
- Founded
- APWC 1996
- NXTC 2015
- Country
- APWC Taiwan
- NXTC United States
- Employees
- APWC N/A
- NXTC N/A
- Industry
- APWC Telecommunications Equipment
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- APWC Industrials
- NXTC Health Care
- Exchange
- APWC Nasdaq
- NXTC Nasdaq
- Market Cap
- APWC 38.9M
- NXTC 40.3M
- IPO Year
- APWC 1997
- NXTC 2019
- Fundamental
- Price
- APWC $1.84
- NXTC $1.37
- Analyst Decision
- APWC
- NXTC Strong Buy
- Analyst Count
- APWC 0
- NXTC 2
- Target Price
- APWC N/A
- NXTC $4.00
- AVG Volume (30 Days)
- APWC 14.0K
- NXTC 43.8K
- Earning Date
- APWC 08-26-2024
- NXTC 11-07-2024
- Dividend Yield
- APWC N/A
- NXTC N/A
- EPS Growth
- APWC N/A
- NXTC N/A
- EPS
- APWC 0.16
- NXTC N/A
- Revenue
- APWC $446,624,000.00
- NXTC N/A
- Revenue This Year
- APWC N/A
- NXTC N/A
- Revenue Next Year
- APWC N/A
- NXTC N/A
- P/E Ratio
- APWC $11.02
- NXTC N/A
- Revenue Growth
- APWC 6.34
- NXTC N/A
- 52 Week Low
- APWC $1.20
- NXTC $1.03
- 52 Week High
- APWC $2.00
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- APWC 57.13
- NXTC 53.73
- Support Level
- APWC $1.76
- NXTC $1.30
- Resistance Level
- APWC $2.00
- NXTC $1.60
- Average True Range (ATR)
- APWC 0.13
- NXTC 0.08
- MACD
- APWC 0.01
- NXTC 0.01
- Stochastic Oscillator
- APWC 52.49
- NXTC 45.91
About APWC Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in owning operating companies engaged in the power cable, telecommunication cable, enameled wire, and electronic cable industry. It also provides project engineering services to customers. Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.